We are looking for breakthrough innovations that can form the basis of new biopharma ventures, from all over the world. From pre-seed to seed stage; at the very beginning, or even before.
Perfectly acceptable for us are ideas where the only person involved is the Post Doc or Professor with a promising discovery but no one else to develop it. We have assembled the complete team in these scenarios.
Even if you believe your project is not yet mature enough to apply, we recommend to get in touch with us. We might think differently, and can help get your project off the ground. Or maybe we can help you get ready.
Already received series A funding or similar? No worries, we might still be able to help you further your reach. Conversely if you are on your Series B and already in the clinic, we are likely not right for you.
Get in touch with us now by filling out the expression of interest. Please note: we are only accepting applications for therapeutic projects. We are no longer accepting applications for medtech, diagnostics or digital health.
Once you submit the form, we will review and come back to you quickly. Although projects can apply at any time, we do have specific dates for meeting with our partners and reviewing incoming deal-flow. The first deadline for the full application is on June 22nd.
We strongly encourage applicants to apply as soon as possible in order to get support crafting their final submission package. In our experience, this early engagement can improve the chances of getting funded.
For the ventures we support, we can provide up to $500,000 (five hundred thousand US dollars). In general, this funding should be used to reach key value inflection milestones and/or to de-risk your project. We will then work with you to raise S eries-A financing or similar and/or to make corporate deals. We have ways into almost all European venture funds and many US funds. We can also support on accessing non-dilutive money.
Our financial support is in the form of a convertible loan on venture-friendly terms. Importantly you stay in charge of whether it converts or not.
After initial selection, we will spend a significant amount of time and money, with external advisors etc. to do a deep dive on your science and business. We will, together with you, work out a detailed plan to solidify strategy, R&D plans, operations and build the company. So even if we eventually decide not to financially support you, this will allow the project to significantly progress.
Sector: Exclusively therapeutics. We do not support medical device, e-health or diagnostic projects. Within therapeutics we are especially interested in breakthrough innovations that form the basis of new biopharma platforms and products. We are interested in all therapeutic sectors (oncology, CNS, immunology, inflammation, metabolic, cardiovascular, antivirals, etc.) and all modalities (small molecules, antibodies, enzymes, peptides, gene therapy, cell therapy, etc.)
Stage: Pre-seed to seed stage, projects. We are fine if the company has not yet been established, we are also fine if it has been. We have also supported biopharma ventures where at the beginning the only person involved was the professor or group leader with a promising discovery but no team to develop it further. If you have already raised a seed or small Series-A round then we could also be interested. If you have completed a significant financing and are well established then it is unlikely we can help.
Location: You can be from anywhere, but we want you to have some corporate presence in the Basel Area . You do not have to be headquartered in Basel. We are confident though, that the Basel Area can sell itself to you.
There is no exact answer here. Exceptional science and a strong commitment from the founder(s) are perhaps the two most important things.
No; we are neutral. If anything, we prefer if you have not because we take care to get the legal stuff correct when incorporating. Getting this wrong at the beginning can create a lot of problems down the road. And we usually (can) also get involved in licensing the IP. Again, something that is crucial to get right at the beginning.
If you are not established, in order to be eligible to receive our funding support, you will need to be incorporated and/or legally registered in the Basel Area. We can help you here.
There are no requirements on staying in the Basel Area once our support is over. But we of course hope you do. There is no better place in Europe than the Basel Area to start and grow a biopharma venture.
We will ask your venture to sign a convertible loan agreement regarding the financial support we provide. We have designed this loan to be “fair” to the founders, and to keep you in charge of the conversion rights. The loan agreement does require the venture to be incorporated and/or be legally registered in the Basel region. We do not ask you for any personal guarantees.
We will most likely structure our financial support around certain development and potential business milestones. These will be agreed on a case by case with each venture.
That depends on the agreements you have, or make, with the inventors or owners of the relevant IP. We can assist you on this. We do not ask for any rights to your IP for BaseLaunch or our partners.